A study has been released investigating the effectiveness of a Melanoma Care Program for patients with early-stage melanoma with varying degrees of fear of cancer recurrence after treatment of their primary melanoma.
The extensive global use of MIA’s online tool for estimating the risk of nodal metastasis in newly diagnosed melanoma patients has prompted an international study to validate its accuracy & improve its precision across diverse populations worldwide.
MIA researchers and clinicians attended the World Congress of Melanoma, held in conjunction with the EADO Congress, in Athens.
MIA researcher Dr Rebecca Simpson has been awarded a CINSW 2024 Early Career Fellowship which supports early & mid-career researchers through the development of research & leadership skills & innovative approaches to research.
A big thank you to our wonderful community of fundraisers. Your dedication and the stories behind your fundraising efforts are inspiring. We are so grateful for your support to help us reach zero deaths from melanoma.
We are excited to commence the work to develop the Roadmap for a National Targeted Skin Cancer Screening Program, and proud to be leading such an important endeavour for the Australian community.
Nature Medicine has published a peer-reviewed paper detailing the experimental glioblastoma cancer treatment developed by Professor Georgina Long AO, Medical Director of Melanoma Institute Australia, paving the way for a clinical trial to be conducted by researchers at The Brain Cancer Centre in Melbourne.
A heartfelt thank you to our incredible community of fundraisers. Your passion, dedication, and endless creativity never cease to inspire us. We are so grateful for your support!
Newly released long-term data from a groundbreaking clinical trial for advanced melanoma patients whose disease had spread to their brain has proven that long-term disease control has been achieved for over 50% of patients given combination immunotherapy as first line treatment.
Prof Richard Scolyer AO has announced that he has decided to step down from his role as Co-Medical Director of Melanoma Institute Australia. Richard has been in this role since January 2017.
